We are live on ! Find out more
BMY icon

Bristol-Myers Squibb

2,364 hedge funds and large institutions have $81.1B invested in Bristol-Myers Squibb in 2023 Q4 according to their latest regulatory filings, with 253 funds opening new positions, 672 increasing their positions, 1,209 reducing their positions, and 240 closing their positions.

New
Increased
Maintained
Reduced
Closed

41% more call options, than puts

Call options by funds: $1.7B | Put options by funds: $1.2B

2.47% more ownership

Funds ownership: 75.18%77.65% (+2.5%)

5% more first-time investments, than exits

New positions opened: 253 | Existing positions closed: 240

1% less funds holding

Funds holding: 2,3882,364 (-24)

11% less capital invested

Capital invested by funds: $91.2B → $81.1B (-$10.2B)

43% less funds holding in top 10

Funds holding in top 10: 4224 (-18)

44% less repeat investments, than reductions

Existing positions increased: 672 | Existing positions reduced: 1,209

Holders
2,364
Holders Change
-24
Holders Change %
-1.01%
% of All Funds
34.46%
Holding in Top 10
24
Holding in Top 10 Change
-18
Holding in Top 10 Change %
-42.86%
% of All Funds
0.35%
New
253
Increased
672
Reduced
1,209
Closed
240
Calls
$1.7B
Puts
$1.2B
Net Calls
+$498M
Net Calls Change
-$7.96M
Name Holding Trade Value Shares
Change
Change in
Stake
BPCE
1426
Bank Pictet & Cie (Europe)
Germany
$577K -$31.5K -600 -5%
FNA
1427
First National Advisers
Nebraska
$576K -$400K -7,620 -40%
APC
1428
Aspire Private Capital
North Carolina
$575K +$410K +7,812 +231%
FNBSF
1429
First National Bank Sioux Falls
South Dakota
$574K
OWP
1430
Obermeyer Wealth Partners
Colorado
$574K +$23.6K +450 +4%
LRPA
1431
L. Roy Papp & Associates
Arizona
$574K
VNA
1432
Valley National Advisers
Pennsylvania
$572K -$119K -2,271 -17%
BFO
1433
Biltmore Family Office
North Carolina
$572K -$61.2K -1,166 -9%
LSA
1434
Lion Street Advisors
Texas
$571K -$35.6K -678 -6%
RIA
1435
Realta Investment Advisors
Delaware
$571K -$238K -4,541 -29%
Empower Advisory Group
1436
Empower Advisory Group
Colorado
$569K +$63K +1,201 +12%
IF
1437
Intrua Financial
Texas
$569K +$141K +2,677 +32%
GC
1438
Guidance Capital
Kentucky
$567K +$81.8K +1,559 +17%
WA
1439
Waverly Advisors
Alabama
$567K +$29.3K +559 +5%
CCWA
1440
CLA (CliftonLarsonAllen) Wealth Advisors
Minnesota
$566K -$19.1K -363 -3%
EWM
1441
Evermay Wealth Management
Virginia
$566K -$118K -2,247 -17%
IFS
1442
Ifrah Financial Services
Arkansas
$564K -$25K -477 -4%
ADL
1443
Asset Dedication LLC
California
$563K -$369K -7,036 -39%
DTC
1444
Davidson Trust Company
Washington
$562K +$10.7K +204 +2%
SIM
1445
Sentry Investment Management
Wisconsin
$562K -$61.8K -1,177 -10%
KMWM
1446
Keudell/Morrison Wealth Management
Oregon
$561K +$13.2K +252 +2%
SFP
1447
Shepherd Financial Partners
Massachusetts
$561K -$6.93K -132 -1%
SIC
1448
Samalin Investment Counsel
New York
$560K -$28.4K -541 -5%
FPB
1449
First PREMIER Bank
South Dakota
$560K -$15.1K -288 -3%
MC
1450
Machina Capital
France
$560K +$46.5K +885 +9%

BMY Hedge Fund Activity: Q4 2023 in Review

2,364 of the 6,860 institutional investors tracked by Wall St. Rank reported a position in Bristol-Myers Squibb (BMY) for Q4 2023, worth a combined $81.1B — down 11% from $91.2B a quarter earlier.

Buyers outnumbered sellers: 253 funds opened new BMY positions and 240 closed out — a net gain of 13 holders — while 672 added to existing stakes and 1,209 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $1.16B. The largest seller was Capital International Investors, cutting an estimated $414M.

  • 2,364 institutional investors held Bristol-Myers Squibb (BMY) as of Q4 2023, down from 2,388 in Q3 2023.
  • Funds reported $81.1B of Bristol-Myers Squibb stock for Q4 2023, down 11% quarter-over-quarter.
  • 253 funds opened new Bristol-Myers Squibb positions in Q4 2023 and 240 closed out, a net change of +13 holders.
  • The largest Bristol-Myers Squibb buyer in Q4 2023 was Morgan Stanley, an estimated $1.16B added.
  • The largest Bristol-Myers Squibb seller in Q4 2023 was Capital International Investors, an estimated $414M sold.

Based on aggregated 13F filings for Q4 2023.